Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph L Kim

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Cancer Discovery|October 3, 2019
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular CarcinomaMegan A Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.
Journal of Medicinal Chemistry|September 22, 2009
Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinolineAdrian L Smith, Frenel F DeMorin, Nick A Paras, et al.
Journal of Medicinal Chemistry|November 18, 2011
Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitorsLaurie B Schenkel, Xin Huang, Alan Cheng, et al.
Frontiers in Immunology|November 6, 2024
Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitorsFelix Scheuplein, Florian Renner, John E Campbell, et al.
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variantsRobert B Perni, Shawn D Britt, John C Court, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2011
Discovery of triazine-benzimidazoles as selective inhibitors of mTOREmily A Peterson, Paul S Andrews, Xuhai Be, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2007
Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitorsBrian L Hodous, Stephanie D Geuns-Meyer, Paul E Hughes, et al.
Science Translational Medicine|November 3, 2017
A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutationsErica K Evans, Alexandra K Gardino, Joseph L Kim, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2004
Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variantsRobert B Perni, Luc J Farmer, Kevin M Cottrell, et al.
Bioorganic & Medicinal Chemistry Letters|December 9, 2008
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinaseVictor J Cee, Alan C Cheng, Karina Romero, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Cancer Discovery|October 3, 2019
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular CarcinomaMegan A Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, et al.
Journal of Medicinal Chemistry|September 22, 2009
Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinolineAdrian L Smith, Frenel F DeMorin, Nick A Paras, et al.
Journal of Medicinal Chemistry|November 18, 2011
Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitorsLaurie B Schenkel, Xin Huang, Alan Cheng, et al.
Frontiers in Immunology|November 6, 2024
Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitorsFelix Scheuplein, Florian Renner, John E Campbell, et al.
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variantsRobert B Perni, Shawn D Britt, John C Court, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2011
Discovery of triazine-benzimidazoles as selective inhibitors of mTOREmily A Peterson, Paul S Andrews, Xuhai Be, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2007
Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitorsBrian L Hodous, Stephanie D Geuns-Meyer, Paul E Hughes, et al.
Science Translational Medicine|November 3, 2017
A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutationsErica K Evans, Alexandra K Gardino, Joseph L Kim, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2004
Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variantsRobert B Perni, Luc J Farmer, Kevin M Cottrell, et al.
Bioorganic & Medicinal Chemistry Letters|December 9, 2008
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinaseVictor J Cee, Alan C Cheng, Karina Romero, et al.
Pageof 3